We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ER-004

News List

The EspeRare Foundation, Pierre Fabre to Develop XLHED Treatment americanpharmaceuticalreview
January 05, 2021
The EspeRare Foundation and the Pierre Fabre group have entered into a license and development collaboration agreement for the development and commercialization of ER-004, a prenatal treatment for XLHED (X-linked Hypohidrotic Ectodermal Dysplasia) ...
Pierre Fabre Selects AGC Biologics as CDMO to manufacture the orphan drug ER-004 prnasia
December 22, 2020
AGC Biologics announced its partnership with Laboratoire Pierre Fabre to manufacture ER-004 – an intra-amniotic drug that will pioneer the treatment of a rare and debilitating genetic disorder.
Global Respiratory Clinics Market will grow at a CAGR of 20.7% over the forecast period - says Absolute Markets Insights prnasia
December 14, 2020
The EspeRare Foundation and the Pierre Fabre group announced today that they have entered into a license and development collaboration agreement for the development and commercialization of ER-004, a prenatal treatment for XLHED (X-linked Hypohidrotic ...